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Abstract The mutation of Asp198 to Asn in the receptor for
glucagon-like peptide-1(7^36)amide (GLP-1) had no e¡ect upon
GLP-1 a⁄nity whereas substitution with Ala greatly reduced
a⁄nity, demonstrating the importance of polarity rather than
negative charge at Asp198. However, the Asp198-Ala mutation
had less e¡ect upon the a⁄nity of Exendin-4, a peptide agonist
that has been shown previously not to require its N-terminus for
high a⁄nity. Moreover, the a⁄nity of a truncated GLP-1 ana-
logue lacking the ¢rst eight residues was not a¡ected by the
Asp198-Ala mutation, demonstrating that Asp198 is required
for maintaining the binding site of the N-terminal region of
GLP-1.
2 2002 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
Glucagon-like peptide-1(7^36)amide (GLP-1; Fig. 1A) is a
30-residue peptide hormone which plays an essential role in
blood glucose homeostasis by augmenting glucose-induced in-
sulin secretion [1]. GLP-1 is a potent ‘incretin’ which has been
shown to increase glucose-dependent insulin secretion [2^4],
decrease glucose-dependent glucagon secretion [5,6] and decel-
erate gastric emptying [7]. In addition, GLP-1 has been shown
to reduce food intake in rats [8] and to stimulate pro-insulin
gene transcription and biosynthesis in pancreatic L-cells [9,10].
These important actions of GLP-1, particularly upon pancre-
atic secretion, highlight the GLP-1 receptor as a target for
therapeutic agents designed to modulate blood sugar levels.
GLP-1 represents a promising approach towards the treat-
ment of hyperglycaemia resulting from diabetes, especially
since its actions, unlike those of sulphonylureas, are glucose-
dependent and hence do not result in hypoglycaemic side ef-
fects [11,12]. However, since the half-life of GLP-1 following
subcutaneous injection is very short [13], future research re-
quires the design of physiologically stable GLP-1 receptor
agonists.
The venom of the Gila monster Heloderma suspectum con-
tains several peptides including a GLP-1 receptor agonist,
Exendin-4, a 39-amino acid peptide with 50% sequence iden-
tity to GLP-1 (Fig. 1A). Interestingly, this peptide can be
truncated by up to eight residues at its N-terminus without
signi¢cant loss of receptor a⁄nity, although the ¢rst two ami-
no acids are essential for e⁄cacy [14^17]. While the N-termini
of GLP-1 and Exendin-4 are almost identical, Exendin-4 con-
tains an extra nine amino acids at the C-terminus which have
been shown to form a ‘Trp cage’ by nuclear magnetic reso-
nance (NMR) analysis when in an aqueous environment [18].
The central region of Exendin-4 (residues 10^30) only shares
eight identical residues with GLP-1. However, NMR analysis
of Exendin-4 has shown this region to be largely helical [18]
and it is interesting to observe that the eight residues shared
by GLP-1 and Exendin-4 in this region all lie on the same face
of an ideal K-helix (Fig. 1B), suggesting that it is this face of
the helix that makes the critical contact with the receptor.
While Exendin-4 can be truncated without loss of receptor
a⁄nity, GLP-1 itself is highly sensitive to N-terminal cleavage
[13,14].
The receptor for GLP-1 is a ‘family B’ G protein-coupled
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Fig. 1. A: The aligned sequences of various GLP-1 receptor pep-
tides used in this analysis. B: A helical wheel showing the sequence
of Exendin-4 from residues Ser11 to Gly29. Residues identical to
those in GLP-1 are shown in white lettering on a black background
while those unique to Exendin-4 are shown in black lettering.
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receptor (GPCR) [19]. GLP-1 binds predominantly to the
N-terminal domain of its receptor [20^22] although other re-
gions of the receptor are also involved (e.g. [21,23]). The aim
of this work is to determine the role of the negatively charged
residue Asp198, located near the extracellular boundary of
transmembrane helix 2, in agonist a⁄nity and activation.
Asp198 is conserved in many family B GPCR families and
has previously been shown to play a role in ligand binding
and receptor activation [21,24^26] although the precise nature
of this residue’s role in agonist and antagonist binding has not
been elucidated.
2. Materials and methods
2.1. Mutagenesis
Asp198 was mutated to alanine or asparagine using the
QuikChange0 Site-Directed Mutagenesis kit (Stratagene, Amsterdam,
The Netherlands). The template vector was pcDNA3 (Invitrogen)
containing the cDNA sequence encoding the rat GLP-1 receptor
cDNA [19].
2.2. Cell culture and transfection
HEK-293 cells were subcultured in Dulbecco’s modi¢ed Eagle’s
medium (DMEM) supplemented with 10% foetal calf serum, 2 mM
L-glutamine, 100 U ml31 penicillin and 100 Wg ml31 streptomycin.
Cells were stably transfected using the SuperFect0 Transfection Re-
agent (Qiagen, Crawley, UK.) and transfected clones were selected by
addition of 800 Wg ml31 G418 antibiotic.
2.3. Membrane preparations
HEK-293 cells cultured to con£uence on ¢veV85-cm2 Petri dishes
(pre-coated with poly-lysine) were washed with phosphate-bu¡ered
saline (PBS). Lysis was achieved by addition of 15 ml ice-cold sterile
water and incubation on ice for 5 min. Cells were thoroughly washed
with ice-cold PBS and scraped from the plates. Membranes were
pelleted by centrifugation and resuspended in 1 ml binding bu¡er
(BB: 2 mM HEPES pH 7.4, 2.5 mM CaCl2, 1 mM MgCl2, 50 mg
l31 bacitracin) and homogenised through a 23G needle. Aliquots were
snap-frozen in liquid N2 and stored at 380‡C. Total protein content
was estimated using the bicinchoninic acid protein assay.
2.4. Radioligand binding assays
Speci¢c binding of 50 pM [125I]GLP-1 or 50 pM [125I]Exendin(9^39)
to membrane preparations was calculated in the absence and presence
of a range of concentrations of unlabelled GLP-1, GLP-1(15^
36)amide, Exendin-4 or Exendin(9^39). Components were mixed in
a total volume of 300 Wl in BB and incubated for 1 h at room temper-
ature. Unbound ligand was removed by washing with cold PBS
through Whatman GF/G ¢bre-glass paper pre-soaked in 5% non-fat
powdered milk. Filters were cut, allowed to dry and radioactivity was
counted using a gamma counter.
2.5. cAMP accumulation assays
Transfected cells were seeded into six-well plates and grown to
con£uence. On the day of the assay, cells were incubated in DMEM
with 2 WCi ml31 [3H]adenine for 2 h at 37‡C. After several washes
with pre-warmed (37‡C) PBS, cells were stimulated for 12 min with
various concentrations of pre-warmed (37‡C) agonist made up in
DMEM containing 0.5 mM 3-isobutyl-1-methylxanthine. The super-
natant was aspirated and the cells lysed using 5% trichloroacetic acid
containing 2.5 nCi ml31 [14C]cAMP. The intracellular [3H]cAMP pro-
duced was puri¢ed (alongside the [14C]cAMP internal column stan-
dard) by the sequential use of Dowex and alumina columns and
counted using a liquid scintillation counter calibrated for dual isotope
counting [27].
2.6. Data analysis
IC50 and EC50 values were calculated using non-linear regression
with the aid of the GraphPad PRISM0 Version 3.0 software (San
Diego, CA, USA). Expression levels were calculated by the equation
Bmax =B0WIC50[L*]31 [28], where B0 is the speci¢c binding of [125I]-
Exendin(9^39) and [L*] is the free concentration of [125I]Exendin-
(9^39).
3. Results and discussion
Substitution of Asp198 for Asn had no signi¢cant e¡ect
upon the a⁄nity for GLP-1, demonstrating that the negative
charge at Asp198 is not critical for a⁄nity. Conversely, the
Asp198-Ala mutant receptor did not display detectable GLP-1
binding (Table 1, Fig. 2A). The absence of detectable
[125I]GLP-1 binding at Asp198-Ala could be due to incorrect
tra⁄cking or folding of the mutant protein. However, since
the receptor maintained high a⁄nity for the antagonist Ex-
endin(9^39) (Table 1, Fig. 2B), it is clearly expressed in the
membrane as a folded protein. Alternatively, the absence of
GLP-1 binding at the Asp198-Ala mutant receptor could be a
result of a reduction in agonist a⁄nity, which easily becomes
undetectable due to the low concentration (50 pM) of
[125I]GLP-1 tracer used in the binding experiments.
Since the Asp198-Ala mutant maintained high a⁄nity for
the antagonist Exendin(9^39), this peptide was used as the
radiolabelled tracer in the subsequent competition binding
assays. From such experiments (Fig. 3A, Table 2) it was ob-
served that the Asp198-Ala mutation resulted in a s 60-fold
reduction in GLP-1 a⁄nity which also manifested itself as a
similar increase in the EC50 value for the activation of the
cAMP pathway in intact HEK-293 cells expressing the wild
type or mutant receptors (Fig. 3B, Table 3).
Exendin(9^39) can be viewed as a truncated analogue of
GLP-1, and therefore the reduction in GLP-1 a⁄nity, coupled
with the maintenance of Exendin(9^39) a⁄nity, suggested the
possibility that Asp198 was involved in forming the structure
of the binding site for the N-terminal region of the natural
agonist. GLP-1 requires its N-terminus for maintaining high
a⁄nity, in addition to it being critical for e⁄cacy [13,14].
Hence disruption of the binding site on the receptor for this
region of the peptide would be expected to reduce GLP-1
a⁄nity. The agonist Exendin-4 is not dependent upon its
N-terminus for maintaining receptor a⁄nity, since it retains
high a⁄nity with the truncation of up to eight residues [14^17]
and hence disruption of the binding site for this region of
Exendin-4 should have little e¡ect upon its a⁄nity. Indeed
this was the case since the Asp198-Ala receptor displayed a
6 8-fold reduction in a⁄nity (Table 2, Fig. 4) which mani-
fested itself in a similar increase in the EC50 value for the
activation of the cAMP pathway (Fig. 4B, Table 3).
To further demonstrate the role of Asp198 in forming the
Table 1
IC50 values (nM) from homologous competition binding assays
Wild type Asp198-Ala Asp198-Asn
[125I]GLP-1/GLP-1 4.4U 1.3 (5) Not detectable 3.2U 0.7 (3)
[125I]Exendin(9^39)/Exendin(9^39) 7.8U 1.8 (7) 36.0U 7.8 (3) 32.5U 19.1 (3)
Bmax (pmol receptor mg31 protein) 67.7U 12.1 (7) 55.6U 7.2 (3) 208.8U 22.0 (3)
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binding site for the N-terminal region of GLP-1, the a⁄nity of
GLP-1(15^36)amide was analysed at the wild type and
Asp198-Ala receptors. If the mutation speci¢cally a¡ects the
binding of the N-terminal region of GLP-1, the mutant would
be expected to have similar a⁄nity to the wild type receptor
for a peptide lacking the N-terminal region. As expected, the
N-terminally truncated analogue GLP-1(15^36)amide
(Fig. 1A) had a reduced a⁄nity (s 35-fold) compared with
GLP-1 for the wild type receptor while in contrast, the
Asp198-Ala receptor displayed only a 2.1-fold reduction in
a⁄nity for GLP-1(15^36)amide. Hence, the s 60-fold reduc-
tion in GLP-1 a⁄nity observed by mutating Asp198 to Ala
was reduced to a 6 4-fold selectivity for GLP-1(15^36)amide
(Table 3). Fig. 5 shows how the mutation of Asp198 to Ala
causes the selective reduction of GLP-1 a⁄nity relative to the
two N-terminally truncated peptide analogues.
Asp198 is conserved in several family B GPCRs. In the
VPAC1 receptor, mutation of the equivalent Asp to Ala re-
sulted in undetectable [125I]VIP binding and a markedly in-
creased EC50 for cAMP production [24]. In the secretin re-
ceptor [25,26], the substitution of the equivalent Asp by Ala
resulted in undetectable receptor expression, while substitu-
tion by Asn resulted in a 25-fold increase in EC50 for adenyl-
ate cyclase activity. Xiao et al. [21] demonstrated that muta-
tion of Asp198 to Ala resulted in a 10-fold reduction in GLP-
1 a⁄nity in whole COS-7 cells transiently expressing the GLP-
1 receptor.
The data presented here suggest that the structure of the
binding site for the N-terminal region of the hormone is de-
pendent upon Asp198. However, this does not necessitate a
direct contact between Asp198 and the N-terminus of the
Table 2
IC50 values (nM) using radiolabelled antagonist [125I]Exendin(9^39)
Wild type Asp198-Ala Fold change
GLP-1 7.9U 3.2 (3) 498.5U 174.9 (3) 63.1
Exendin-4 1.8U 0.4 (3) 13.9U 2.4 (3) 7.7
GLP-1(15^36)amide 287.3U 110.3 (3) 1034.0U 118.9 (3) 3.6
Fig. 2. Homologous competition binding curves for wild type
(squares), Asp198-Ala (triangles) and Asp198-Asn (circles) receptors
for GLP-1 (A) and Exendin(9^39) (B) (see Tables 1 and 2 for val-
ues). All curves represent one of at least three independent experi-
ments for which each point represents the mean of triplicate values
with S.E.M. displayed as error bars. Counts were normalised to the
maximal speci¢c binding within each data set except for the GLP-1
binding to Asp198-Ala (A) which was normalised to the maximal
binding in the wild type data set.
Fig. 3. A: Non-homologous competition binding curve using radio-
labelled antagonist and unlabelled GLP-1. B: cAMP accumulation
curves for GLP-1 (squares=wild type; triangles=Asp198-Ala).
Curves represent one of at least three independent experiments (see
Tables 1 and 2). Each point represents the mean of triplicates with
S.E.M. displayed as error bars.
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hormone. Rather, the local structure of this region of the
hormone-binding site, located close to the boundary of trans-
membrane helix 2 and the ¢rst extracellular loop, likely re-
quires a hydrogen bond from the side chain of Asp198, which
can be maintained by substitution with Asn but not Ala. The
absence of this hydrogen bond does not completely destroy
the ability of the receptor to form its active state and activate
its G protein. Rather, it appears to reduce agonist a⁄nity so
that receptor activation and the subsequent intracellular sig-
nalling events are observed at higher agonist concentrations
compared to the wild type receptor.
Although the N-terminal domain of the GLP-1 receptor has
been demonstrated to form a direct hormone^receptor inter-
action [20^22], the ¢rst extracellular loop has also been impli-
cated in agonist binding (e.g. [21]). The data presented here
further demonstrate that this region is necessary for the for-
mation of the binding site of the GLP-1 hormone. In addition,
we have shown that a critical determinant for maintaining this
region of the binding site is the hydrogen bonding capability,
rather than the negative charge, of Asp198. Moreover, we
have identi¢ed that this region on the receptor is responsible
for forming the binding site of the N-terminal region of the
hormone.
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